Cyclarity Therapeutics Secures Approval for First-in-Human Clinical Trial
NOVATO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Cyclarity Therapeutics is pleased to announce regulatory approval to begin its first-in-human...
NOVATO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Cyclarity Therapeutics is pleased to announce regulatory approval to begin its first-in-human...
BOSTON, MASSACHUSETTS, Jan. 07, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing...
BETHLEHEM, Pa., Jan. 07, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline on Tuesday, January 7th...
Over 300 Participants Have Completed Cumulative Six Months of Cytisinicline Treatment in the ORCA-OL Trial, Completing the Long-Term Exposure Requirement...
VANCOUVER, British Columbia and BOSTON, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company...
Six months after its unveiling, the IRO platform is now being deployed to customersLONDON, Jan. 07, 2025 (GLOBE NEWSWIRE) --...
QUANTRO’s proprietary time-resolved functional transcriptomic discovery platform accelerates target screening for complex indications in oncology and inflammationQUANTRO CEO Dr. Michael...
WOBURN, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Cytrellis Biosystems, Inc., a pioneer in novel medical aesthetic solutions, today announced...
MARLBOROUGH, Mass. and YOKNEAM ILIT, Israel, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a...
* Patients in Study Reported Lower Pain Levels, Better Sleep Quality, and Improved Wellbeing * Disease Activity Score Decreased by 19.2%,...
• Second regulatory designation for Restem-L, a lead ULSC program, following the recent Orphan Drug Designation• Recently reported Phase 1...
PRINCETON, N.J., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) formerly Acasti Pharma Inc. (Nasdaq: ACST) (Grace...
MONTREAL and CHARLOTTE, N.C., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the “Company” or “Milestone”), today...
BRISBANE, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform...
CUPERTINO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage...
TORONTO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a leading...
MINNEAPOLIS, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire) will release financial results for the...
CAMBRIDGE, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a clinical-stage biopharmaceutical company focused on...
Breakthrough Therapy Designation granted based on key positive data from the Phase 2b (RIZE) study and current unmet medical need...
AUSTIN, Texas, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Erisyon, a leading provider of single-molecule proteomics technology, today announced that it...